<DOC>
	<DOCNO>NCT00823862</DOCNO>
	<brief_summary>To determine safety , tolerability , preliminary efficacy escalate dos SD-101 alone SD-101 plus ribavirin subject chronic hepatitis C prior therapy .</brief_summary>
	<brief_title>Safety Study SD-101 ( Novel C Type Toll-like Receptor 9 ( TLR9 ) Agonist ) Treatment Chronic Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Signed , write , inform consent Male female subject , 18 55 year age . Subject must chronic infection HCV , genotype 1 . Serum HCVRNA concentration 100,000 IU/mL 10,000,000 IU/mL No prior treatment HCV . Must negative hepatitis B ( HBV ) human immunodeficiency virus ( HIV ) . Must willing use dual method contraception ( i.e. , barrier spermicide ; birth control pill barrier ) study . No known hypersensitivity study medication drug chemically relate study . Prior treatment IFNbased therapy and/or antiviral therapy . Women ongoing pregnancy breast feed male partner woman pregnant . Reduced kidney function . Presence concomitant liver diseases Signs symptom hepatocellular carcinoma . Thyroid disease currently poorly control prescribed medication . History hemoglobinopathy . Evidence severe retinopathy . Other serious medical condition , include human immunodeficiency virus , cancer ( exclude nonmelanoma skin cancer ) , evidence drug alcohol abuse . Subjects document presumed coronary artery disease , pulmonary disease , cerebrovascular disease Clinically significant acute chronic illness . History severe psychiatric disease , especially depression , characterize suicide attempt , hospitalization psychiatric disease , period disability result psychiatric disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HCV</keyword>
	<keyword>Immunostimulatory sequence ( ISS )</keyword>
	<keyword>TLR9 ( toll-like receptor 9 )</keyword>
	<keyword>interferon ( IFN )</keyword>
	<keyword>ribavirin</keyword>
</DOC>